Please login to the form below

Not currently logged in


This page shows the latest F-Star news and features for those working in and with pharma, biotech and healthcare.

Cancer disruptor F Star names next CEO

Cancer disruptor F Star names next CEO

Dr Eliot Forster takes reins from Dr John Haurum. UK-based biotech F-star has named Dr Eliot Forster as its new chief executive. ... I believe that F-star’s first-in-class molecules bring together in a single form, the full power of IO and combinations.

Latest news

  • BMS taps F-star Alpha for immuno-oncology drug BMS taps F-star Alpha for immuno-oncology drug

    Drug in development for breast and stomach cancers. Bristol-Myers Squibb (BMS) has hatched a plan to buy Austrian biotech F-star Alpha in order to claim rights to FS102, a ... F-star has its headquarters in Vienna but runs its research operations out of

  • f-star wins €15m investment

    Antibody specialist f-star secures funding from existing investors and adds new members to its supervisory board. ... f-star, a company developing antibody-based products, has secured 15m of new financing.

  • Survival strategy

    During November and December 2010 there were five Big Pharma discovery deals involving Boehringer Ingelheim (with f-star), S-A (with Avila Therapeutics), Pfizer (with Phylogica), Tanabe Research Laboratories (with Anaphore) ... f-star/Boehringer

  • PM Society Awards 2005

    These days you're lucky if you can give them a three-star hotel and a f ing biro. ... He also issued a thinly-veiled warning to any entrants who had been honoured with a highly commended': Congratulations and all that but stay in your f ing seat.

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    525. F-star Alpha/BMS. Option to acquire F-star Alpha. Includes FS102 a P1 ready treatment for HER2 positive patients with breast /   gastric cancer.

  • Pharma deals during October 2014 Pharma deals during October 2014

    A major feature throughout 2014 has been the deployment of options. This month is no exception with Bristol-Myers Squibb (BMS) securing an exclusive option to acquire F-star Alpha gaining

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....